Loading…
High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes
Background: Angiogenic factors have an essential role in normal and pathologic angiogenesis. However, the clinical implication of angiogenic factor expression in myelodysplastic syndromes (MDS) remains unclear. Methods: In this study, we sought to investigate the prognostic impact of the expression...
Saved in:
| Published in: | British journal of cancer 2011-09, Vol.105 (7), p.975-982 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c536t-5cb414b6e0b86362e8ba4ae91ec4ec06d77238e328a639972e6b930c1abc11783 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c536t-5cb414b6e0b86362e8ba4ae91ec4ec06d77238e328a639972e6b930c1abc11783 |
| container_end_page | 982 |
| container_issue | 7 |
| container_start_page | 975 |
| container_title | British journal of cancer |
| container_volume | 105 |
| creator | Cheng, C-L Hou, H-A Jhuang, J-Y Lin, C-W Chen, C-Y Tang, J-L Chou, W-C Tseng, M-H Yao, M Huang, S-Y Ko, B-S Hsu, S-C Wu, S-J Tsay, W Chen, Y-C Tien, H-F |
| description | Background:
Angiogenic factors have an essential role in normal and pathologic angiogenesis. However, the clinical implication of angiogenic factor expression in myelodysplastic syndromes (MDS) remains unclear.
Methods:
In this study, we sought to investigate the prognostic impact of the expression of genes encoding angiopoietin-1 (
Ang-1
),
Ang-2
, the receptor
Tie2
, vascular endothelial growth factor-A (
VEGF-A
) and
VEGF-C
in the bone marrow (BM) in 208 patients with newly diagnosed primary MDS.
Results:
BM
Ang-1
expression was significantly higher in MDS patients, especially those with higher-risk subtypes, than in normal controls. With a median follow-up time of 32.9 months, the disease transformed to acute leukaemia more frequently in the patients bearing higher
Ang-1
expression than in those with lower expression (31.5%
vs
18.6%,
P
=0.023). The MDS patients with higher
Ang-1
expression had shorter overall survival than those with lower expression (median 20.8±4.5 months
vs
63.3±17.8 months,
P |
| doi_str_mv | 10.1038/bjc.2011.340 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3185953</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1008840377</sourcerecordid><originalsourceid>FETCH-LOGICAL-c536t-5cb414b6e0b86362e8ba4ae91ec4ec06d77238e328a639972e6b930c1abc11783</originalsourceid><addsrcrecordid>eNp9ks-P1CAUxxujccfVm2dDTMx6sCM_2gKXTcxGXZNNvOiZUPraYdJChXbW-Rv8p5c646ya6AEIvA_f7-Pxsuw5wWuCmXhbb82aYkLWrMAPshUpGc2JoPxhtsIY8xxLis-yJzFu01ZiwR9nZ5QILiSrVtmPa9ttUO0doEGH4G-Rdp31o7cwWZcTBN_HADFa75CNKYisa2CENLkJjd4HNAbfOR8na1CrzZRO2jTiHHZ2p_vEo1FPNuER3dppg4Y99L7Zx7HXPy_FvWuCHyA-zR61uo_w7LieZ18_vP9ydZ3ffP746erdTW5KVk15aeqCFHUFuBYVqyiIWhcaJAFTgMFVwzllAhgVumJScgpVLRk2RNeGEC7YeXZ50B3neoDGpNSC7tUYbCrBXnlt1Z8RZzeq8zvFiChlyZLAxVEg-G8zxEkNNhroe-3Az1EJWQiKOVmsXv-XJBgLUWDGeUJf_oVu_RxcKsSix7AUYoHeHCATfIwB2lPWBKulHVRqB7W0g0rtkPAXv7_0BP_6_wS8OgI6Gt23QTtj4z1XlDzZLr75gYsp5DoI98n9wxgdeKenOcBJMEELsyB3K9Xa3A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>894309887</pqid></control><display><type>article</type><title>High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes</title><source>PubMed Central</source><creator>Cheng, C-L ; Hou, H-A ; Jhuang, J-Y ; Lin, C-W ; Chen, C-Y ; Tang, J-L ; Chou, W-C ; Tseng, M-H ; Yao, M ; Huang, S-Y ; Ko, B-S ; Hsu, S-C ; Wu, S-J ; Tsay, W ; Chen, Y-C ; Tien, H-F</creator><creatorcontrib>Cheng, C-L ; Hou, H-A ; Jhuang, J-Y ; Lin, C-W ; Chen, C-Y ; Tang, J-L ; Chou, W-C ; Tseng, M-H ; Yao, M ; Huang, S-Y ; Ko, B-S ; Hsu, S-C ; Wu, S-J ; Tsay, W ; Chen, Y-C ; Tien, H-F</creatorcontrib><description>Background:
Angiogenic factors have an essential role in normal and pathologic angiogenesis. However, the clinical implication of angiogenic factor expression in myelodysplastic syndromes (MDS) remains unclear.
Methods:
In this study, we sought to investigate the prognostic impact of the expression of genes encoding angiopoietin-1 (
Ang-1
),
Ang-2
, the receptor
Tie2
, vascular endothelial growth factor-A (
VEGF-A
) and
VEGF-C
in the bone marrow (BM) in 208 patients with newly diagnosed primary MDS.
Results:
BM
Ang-1
expression was significantly higher in MDS patients, especially those with higher-risk subtypes, than in normal controls. With a median follow-up time of 32.9 months, the disease transformed to acute leukaemia more frequently in the patients bearing higher
Ang-1
expression than in those with lower expression (31.5%
vs
18.6%,
P
=0.023). The MDS patients with higher
Ang-1
expression had shorter overall survival than those with lower expression (median 20.8±4.5 months
vs
63.3±17.8 months,
P
<0.001). Multivariate analyses showed that higher
Ang-1
expression was an independent unfavourable prognostic factor for overall survival. There was no impact of the expression of other angiogenic factors on survival.
Conclusion:
BM
Ang-1
expression may serve as a new biomarker to predict clinical outcome in MDS patients.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2011.340</identifier><identifier>PMID: 21878936</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/1620/1342 ; 692/699/67/1857 ; 692/699/67/1990/1673 ; 692/700/1750 ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Angiopoietin-1 - genetics ; Angiopoietin-1 - metabolism ; Angiopoietin-2 - genetics ; Angiopoietin-2 - metabolism ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Bone Marrow - metabolism ; Cancer Research ; Case-Control Studies ; Cohort Studies ; Drug Resistance ; Epidemiology ; Female ; Hematologic and hematopoietic diseases ; Humans ; Immunoenzyme Techniques ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Middle Aged ; Molecular Diagnostics ; Molecular Medicine ; Myelodysplastic syndromes ; Myelodysplastic Syndromes - genetics ; Myelodysplastic Syndromes - metabolism ; Myelodysplastic Syndromes - mortality ; Oncology ; Prognosis ; Receptor, TIE-2 - genetics ; Receptor, TIE-2 - metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; RNA, Messenger - genetics ; Survival Rate ; Tumors ; Vascular Endothelial Growth Factor A - genetics ; Vascular Endothelial Growth Factor A - metabolism ; Vascular Endothelial Growth Factor C - genetics ; Vascular Endothelial Growth Factor C - metabolism ; Young Adult</subject><ispartof>British journal of cancer, 2011-09, Vol.105 (7), p.975-982</ispartof><rights>The Author(s) 2011</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Sep 27, 2011</rights><rights>Copyright © 2011 Cancer Research UK 2011 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c536t-5cb414b6e0b86362e8ba4ae91ec4ec06d77238e328a639972e6b930c1abc11783</citedby><cites>FETCH-LOGICAL-c536t-5cb414b6e0b86362e8ba4ae91ec4ec06d77238e328a639972e6b930c1abc11783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185953/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185953/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24578877$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21878936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheng, C-L</creatorcontrib><creatorcontrib>Hou, H-A</creatorcontrib><creatorcontrib>Jhuang, J-Y</creatorcontrib><creatorcontrib>Lin, C-W</creatorcontrib><creatorcontrib>Chen, C-Y</creatorcontrib><creatorcontrib>Tang, J-L</creatorcontrib><creatorcontrib>Chou, W-C</creatorcontrib><creatorcontrib>Tseng, M-H</creatorcontrib><creatorcontrib>Yao, M</creatorcontrib><creatorcontrib>Huang, S-Y</creatorcontrib><creatorcontrib>Ko, B-S</creatorcontrib><creatorcontrib>Hsu, S-C</creatorcontrib><creatorcontrib>Wu, S-J</creatorcontrib><creatorcontrib>Tsay, W</creatorcontrib><creatorcontrib>Chen, Y-C</creatorcontrib><creatorcontrib>Tien, H-F</creatorcontrib><title>High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background:
Angiogenic factors have an essential role in normal and pathologic angiogenesis. However, the clinical implication of angiogenic factor expression in myelodysplastic syndromes (MDS) remains unclear.
Methods:
In this study, we sought to investigate the prognostic impact of the expression of genes encoding angiopoietin-1 (
Ang-1
),
Ang-2
, the receptor
Tie2
, vascular endothelial growth factor-A (
VEGF-A
) and
VEGF-C
in the bone marrow (BM) in 208 patients with newly diagnosed primary MDS.
Results:
BM
Ang-1
expression was significantly higher in MDS patients, especially those with higher-risk subtypes, than in normal controls. With a median follow-up time of 32.9 months, the disease transformed to acute leukaemia more frequently in the patients bearing higher
Ang-1
expression than in those with lower expression (31.5%
vs
18.6%,
P
=0.023). The MDS patients with higher
Ang-1
expression had shorter overall survival than those with lower expression (median 20.8±4.5 months
vs
63.3±17.8 months,
P
<0.001). Multivariate analyses showed that higher
Ang-1
expression was an independent unfavourable prognostic factor for overall survival. There was no impact of the expression of other angiogenic factors on survival.
Conclusion:
BM
Ang-1
expression may serve as a new biomarker to predict clinical outcome in MDS patients.</description><subject>631/250/1620/1342</subject><subject>692/699/67/1857</subject><subject>692/699/67/1990/1673</subject><subject>692/700/1750</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiopoietin-1 - genetics</subject><subject>Angiopoietin-1 - metabolism</subject><subject>Angiopoietin-2 - genetics</subject><subject>Angiopoietin-2 - metabolism</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bone Marrow - metabolism</subject><subject>Cancer Research</subject><subject>Case-Control Studies</subject><subject>Cohort Studies</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Diagnostics</subject><subject>Molecular Medicine</subject><subject>Myelodysplastic syndromes</subject><subject>Myelodysplastic Syndromes - genetics</subject><subject>Myelodysplastic Syndromes - metabolism</subject><subject>Myelodysplastic Syndromes - mortality</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Receptor, TIE-2 - genetics</subject><subject>Receptor, TIE-2 - metabolism</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>RNA, Messenger - genetics</subject><subject>Survival Rate</subject><subject>Tumors</subject><subject>Vascular Endothelial Growth Factor A - genetics</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><subject>Vascular Endothelial Growth Factor C - genetics</subject><subject>Vascular Endothelial Growth Factor C - metabolism</subject><subject>Young Adult</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9ks-P1CAUxxujccfVm2dDTMx6sCM_2gKXTcxGXZNNvOiZUPraYdJChXbW-Rv8p5c646ya6AEIvA_f7-Pxsuw5wWuCmXhbb82aYkLWrMAPshUpGc2JoPxhtsIY8xxLis-yJzFu01ZiwR9nZ5QILiSrVtmPa9ttUO0doEGH4G-Rdp31o7cwWZcTBN_HADFa75CNKYisa2CENLkJjd4HNAbfOR8na1CrzZRO2jTiHHZ2p_vEo1FPNuER3dppg4Y99L7Zx7HXPy_FvWuCHyA-zR61uo_w7LieZ18_vP9ydZ3ffP746erdTW5KVk15aeqCFHUFuBYVqyiIWhcaJAFTgMFVwzllAhgVumJScgpVLRk2RNeGEC7YeXZ50B3neoDGpNSC7tUYbCrBXnlt1Z8RZzeq8zvFiChlyZLAxVEg-G8zxEkNNhroe-3Az1EJWQiKOVmsXv-XJBgLUWDGeUJf_oVu_RxcKsSix7AUYoHeHCATfIwB2lPWBKulHVRqB7W0g0rtkPAXv7_0BP_6_wS8OgI6Gt23QTtj4z1XlDzZLr75gYsp5DoI98n9wxgdeKenOcBJMEELsyB3K9Xa3A</recordid><startdate>20110927</startdate><enddate>20110927</enddate><creator>Cheng, C-L</creator><creator>Hou, H-A</creator><creator>Jhuang, J-Y</creator><creator>Lin, C-W</creator><creator>Chen, C-Y</creator><creator>Tang, J-L</creator><creator>Chou, W-C</creator><creator>Tseng, M-H</creator><creator>Yao, M</creator><creator>Huang, S-Y</creator><creator>Ko, B-S</creator><creator>Hsu, S-C</creator><creator>Wu, S-J</creator><creator>Tsay, W</creator><creator>Chen, Y-C</creator><creator>Tien, H-F</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110927</creationdate><title>High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes</title><author>Cheng, C-L ; Hou, H-A ; Jhuang, J-Y ; Lin, C-W ; Chen, C-Y ; Tang, J-L ; Chou, W-C ; Tseng, M-H ; Yao, M ; Huang, S-Y ; Ko, B-S ; Hsu, S-C ; Wu, S-J ; Tsay, W ; Chen, Y-C ; Tien, H-F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c536t-5cb414b6e0b86362e8ba4ae91ec4ec06d77238e328a639972e6b930c1abc11783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>631/250/1620/1342</topic><topic>692/699/67/1857</topic><topic>692/699/67/1990/1673</topic><topic>692/700/1750</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiopoietin-1 - genetics</topic><topic>Angiopoietin-1 - metabolism</topic><topic>Angiopoietin-2 - genetics</topic><topic>Angiopoietin-2 - metabolism</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bone Marrow - metabolism</topic><topic>Cancer Research</topic><topic>Case-Control Studies</topic><topic>Cohort Studies</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Diagnostics</topic><topic>Molecular Medicine</topic><topic>Myelodysplastic syndromes</topic><topic>Myelodysplastic Syndromes - genetics</topic><topic>Myelodysplastic Syndromes - metabolism</topic><topic>Myelodysplastic Syndromes - mortality</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Receptor, TIE-2 - genetics</topic><topic>Receptor, TIE-2 - metabolism</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>RNA, Messenger - genetics</topic><topic>Survival Rate</topic><topic>Tumors</topic><topic>Vascular Endothelial Growth Factor A - genetics</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><topic>Vascular Endothelial Growth Factor C - genetics</topic><topic>Vascular Endothelial Growth Factor C - metabolism</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheng, C-L</creatorcontrib><creatorcontrib>Hou, H-A</creatorcontrib><creatorcontrib>Jhuang, J-Y</creatorcontrib><creatorcontrib>Lin, C-W</creatorcontrib><creatorcontrib>Chen, C-Y</creatorcontrib><creatorcontrib>Tang, J-L</creatorcontrib><creatorcontrib>Chou, W-C</creatorcontrib><creatorcontrib>Tseng, M-H</creatorcontrib><creatorcontrib>Yao, M</creatorcontrib><creatorcontrib>Huang, S-Y</creatorcontrib><creatorcontrib>Ko, B-S</creatorcontrib><creatorcontrib>Hsu, S-C</creatorcontrib><creatorcontrib>Wu, S-J</creatorcontrib><creatorcontrib>Tsay, W</creatorcontrib><creatorcontrib>Chen, Y-C</creatorcontrib><creatorcontrib>Tien, H-F</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheng, C-L</au><au>Hou, H-A</au><au>Jhuang, J-Y</au><au>Lin, C-W</au><au>Chen, C-Y</au><au>Tang, J-L</au><au>Chou, W-C</au><au>Tseng, M-H</au><au>Yao, M</au><au>Huang, S-Y</au><au>Ko, B-S</au><au>Hsu, S-C</au><au>Wu, S-J</au><au>Tsay, W</au><au>Chen, Y-C</au><au>Tien, H-F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2011-09-27</date><risdate>2011</risdate><volume>105</volume><issue>7</issue><spage>975</spage><epage>982</epage><pages>975-982</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Background:
Angiogenic factors have an essential role in normal and pathologic angiogenesis. However, the clinical implication of angiogenic factor expression in myelodysplastic syndromes (MDS) remains unclear.
Methods:
In this study, we sought to investigate the prognostic impact of the expression of genes encoding angiopoietin-1 (
Ang-1
),
Ang-2
, the receptor
Tie2
, vascular endothelial growth factor-A (
VEGF-A
) and
VEGF-C
in the bone marrow (BM) in 208 patients with newly diagnosed primary MDS.
Results:
BM
Ang-1
expression was significantly higher in MDS patients, especially those with higher-risk subtypes, than in normal controls. With a median follow-up time of 32.9 months, the disease transformed to acute leukaemia more frequently in the patients bearing higher
Ang-1
expression than in those with lower expression (31.5%
vs
18.6%,
P
=0.023). The MDS patients with higher
Ang-1
expression had shorter overall survival than those with lower expression (median 20.8±4.5 months
vs
63.3±17.8 months,
P
<0.001). Multivariate analyses showed that higher
Ang-1
expression was an independent unfavourable prognostic factor for overall survival. There was no impact of the expression of other angiogenic factors on survival.
Conclusion:
BM
Ang-1
expression may serve as a new biomarker to predict clinical outcome in MDS patients.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21878936</pmid><doi>10.1038/bjc.2011.340</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2011-09, Vol.105 (7), p.975-982 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3185953 |
| source | PubMed Central |
| subjects | 631/250/1620/1342 692/699/67/1857 692/699/67/1990/1673 692/700/1750 Adolescent Adult Aged Aged, 80 and over Angiopoietin-1 - genetics Angiopoietin-1 - metabolism Angiopoietin-2 - genetics Angiopoietin-2 - metabolism Biological and medical sciences Biomedical and Life Sciences Biomedicine Bone Marrow - metabolism Cancer Research Case-Control Studies Cohort Studies Drug Resistance Epidemiology Female Hematologic and hematopoietic diseases Humans Immunoenzyme Techniques Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Molecular Diagnostics Molecular Medicine Myelodysplastic syndromes Myelodysplastic Syndromes - genetics Myelodysplastic Syndromes - metabolism Myelodysplastic Syndromes - mortality Oncology Prognosis Receptor, TIE-2 - genetics Receptor, TIE-2 - metabolism Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger - genetics Survival Rate Tumors Vascular Endothelial Growth Factor A - genetics Vascular Endothelial Growth Factor A - metabolism Vascular Endothelial Growth Factor C - genetics Vascular Endothelial Growth Factor C - metabolism Young Adult |
| title | High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T13%3A26%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20bone%20marrow%20angiopoietin-1%20expression%20is%20an%20independent%20poor%20prognostic%20factor%20for%20survival%20in%20patients%20with%20myelodysplastic%20syndromes&rft.jtitle=British%20journal%20of%20cancer&rft.au=Cheng,%20C-L&rft.date=2011-09-27&rft.volume=105&rft.issue=7&rft.spage=975&rft.epage=982&rft.pages=975-982&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2011.340&rft_dat=%3Cproquest_pubme%3E1008840377%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c536t-5cb414b6e0b86362e8ba4ae91ec4ec06d77238e328a639972e6b930c1abc11783%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=894309887&rft_id=info:pmid/21878936&rfr_iscdi=true |